PL1613350T3 - Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα - Google Patents

Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα

Info

Publication number: PL1613350T3
Authority: PL; Poland
Prior art keywords: tnf; therapy; autoimmune disease; patient; inadequate response
Prior art date: 2003-04-09

Application number

PL04759142T

Other languages

English (en)

Inventor

Mark Benyunes

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-09

Filing date

2004-04-06

Publication date

2009-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1613350(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-06 Application filed by Genentech Inc filed Critical Genentech Inc

2009-08-31 Publication of PL1613350T3 publication Critical patent/PL1613350T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Neurology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)

PL04759142T 2003-04-09 2004-04-06 Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα PL1613350T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46148103P	2003-04-09	2003-04-09
EP04759142A EP1613350B1 (en)	2003-04-09	2004-04-06	Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
PCT/US2004/010509 WO2004091657A2 (en)	2003-04-09	2004-04-06	Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor

Publications (1)

Publication Number	Publication Date
PL1613350T3 true PL1613350T3 (pl)	2009-08-31

Family

ID=33299824

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04759142T PL1613350T3 (pl)	2003-04-09	2004-04-06	Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα

Country Status (31)

Country	Link
US (4)	US20040202658A1 (pl)
EP (2)	EP2062916A3 (pl)
JP (3)	JP2006522811A (pl)
KR (2)	KR20110044809A (pl)
CN (2)	CN101371924A (pl)
AT (1)	ATE425766T1 (pl)
AU (1)	AU2004229376B2 (pl)
BR (1)	BRPI0409534A (pl)
CA (1)	CA2519870A1 (pl)
CR (1)	CR8033A (pl)
CY (1)	CY1109127T1 (pl)
DE (1)	DE602004020061D1 (pl)
DK (1)	DK1613350T3 (pl)
EC (1)	ECSP056082A (pl)
ES (1)	ES2322267T3 (pl)
HR (2)	HRP20090325T1 (pl)
IL (2)	IL171038A (pl)
MA (1)	MA27838A1 (pl)
ME (1)	ME00426B (pl)
MX (1)	MXPA05010778A (pl)
NO (1)	NO20055253L (pl)
NZ (2)	NZ587776A (pl)
PL (1)	PL1613350T3 (pl)
PT (1)	PT1613350E (pl)
RS (1)	RS51686B (pl)
RU (1)	RU2358762C9 (pl)
SI (1)	SI1613350T1 (pl)
TN (1)	TNSN05234A1 (pl)
UA (2)	UA91961C2 (pl)
WO (1)	WO2004091657A2 (pl)
ZA (1)	ZA200507805B (pl)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1043312B (en)	1999-05-07	2006-07-28	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
CN1373672A (zh) *	1999-07-12	2002-10-09	杰南技术公司	应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
KR20040094705A (ko)	2002-02-21	2004-11-10	듀크 유니버시티	자가면역질환에 대한 시약 및 치료 방법
US20090217404A1 (en) *	2002-09-27	2009-08-27	Lowe Scott W	Cell-based RNA interference and related methods and compositions
WO2004056312A2 (en) *	2002-12-16	2004-07-08	Genentech, Inc.	Immunoglobulin variants and uses thereof
DK1599573T3 (da) *	2003-02-17	2013-07-08	Cold Spring Harbor Lab	Model til at studere genernes rolle i tumorresistens over for kemoterapi
US20090186839A1 (en) *	2003-02-17	2009-07-23	Cold Spring Harbor Laboratory	Model for studying the role of genes in chemoresistance
EP1460088A1 (en)	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
PT1613350E (pt)	2003-04-09	2009-06-24	Genentech Inc	Terapia de doença auto-imune num paciente com uma resposta inadequada a um inibidor de tnf-alfa
CA2897608C (en) *	2003-05-09	2018-07-31	Duke University	Cd20-specific antibodies and methods employing same
AR044388A1 (es) *	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
BRPI0412629A (pt) *	2003-08-29	2006-09-26	Genentech Inc	método de tratamento de disfunção ocular em mamìferos
EA025962B1 (ru)	2003-11-05	2017-02-28	Роше Гликарт Аг	АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
CA2562243A1 (en) *	2004-04-16	2005-12-08	Genetech, Inc.	Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
AR049200A1 (es) *	2004-06-04	2006-07-05	Genentech Inc	Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
RU2396980C2 (ru) *	2004-06-04	2010-08-20	Дженентек, Инк.	Способ лечения волчанки
BRPI0513100A (pt) *	2004-07-22	2007-10-23	Genentech Inc	métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
EA012464B1 (ru)	2004-08-04	2009-10-30	Эпплайд Молекьюлар Эволюшн, Инк.	Антитело против cd20 и его применение
KR20070100228A (ko) *	2004-10-05	2007-10-10	제넨테크, 인크.	혈관염의 치료 방법
US8137907B2 (en) *	2005-01-03	2012-03-20	Cold Spring Harbor Laboratory	Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
EP1841454A4 (en) *	2005-01-13	2009-07-22	Genentech Inc	PROCESSING METHOD
KR101289537B1 (ko) *	2005-02-15	2013-07-31	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
US8444973B2 (en) *	2005-02-15	2013-05-21	Duke University	Anti-CD19 antibodies and uses in B cell disorders
US20060263357A1 (en) *	2005-05-05	2006-11-23	Tedder Thomas F	Anti-CD19 antibody therapy for autoimmune disease
EA015584B1 (ru) *	2005-03-23	2011-10-31	Генмаб А/С	Антитело к cd38 человека и его применение
AR053579A1 (es) *	2005-04-15	2007-05-09	Genentech Inc	Tratamiento de la enfermedad inflamatoria intestinal (eii)
JP2008545958A (ja) *	2005-05-20	2008-12-18	ジェネンテック・インコーポレーテッド	自己免疫性疾患の被検体の生体試料の前処理
WO2007053184A2 (en)	2005-05-31	2007-05-10	Cold Spring Harbor Laboratory	Methods for producing micrornas
EP1904101A4 (en) *	2005-06-08	2011-06-15	Univ Duke	ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
RU2478709C2 (ru) *	2005-07-21	2013-04-10	Эбботт Лэборетриз	ЭКСПРЕССИЯ МНОЖЕСТВА ГЕНОВ, ВКЛЮЧАЯ sORF-КОНСТРУКЦИИ, И СПОСОБЫ ЭКСПРЕССИРОВАНИЯ ИММУНОГЛОБУЛИНА
BRPI0618217A2 (pt) *	2005-11-01	2011-08-23	Novartis Ag	usos de anticorpos anti-cd40
US8470318B2 (en) *	2005-11-07	2013-06-25	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
MY149159A (en) *	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
JP2009532336A (ja) *	2006-03-06	2009-09-10	メディミューン，エルエルシー	ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用
EP2540741A1 (en)	2006-03-06	2013-01-02	Aeres Biomedical Limited	Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP6084761B2 (ja) *	2006-04-05	2017-02-22	ザロックフェラーユニバーシティー	抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
AU2007253740A1 (en)	2006-05-18	2007-11-29	Molecular Profiling Institute, Inc.	System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) *	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
DK2066349T3 (da) *	2006-09-08	2012-07-09	Medimmune Llc	Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme
US8420330B2 (en)	2011-07-15	2013-04-16	Myra A. Lipes	Diagnosis and treatment of cardiac troponin 1 (cTn1) autoantibody-mediated heart disease
GB0707208D0 (en) *	2007-04-13	2007-05-23	Istituto Superiore Di Sanito	Novel disease treatments
EP2174667B1 (en) *	2007-07-26	2017-01-04	Osaka University	Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
AU2008311815B2 (en)	2007-10-19	2014-02-06	Seagen Inc.	CD19 binding agents and uses thereof
WO2009121690A1 (en) *	2008-03-13	2009-10-08	Biotest Ag	Agent for treating disease
MX2010010026A (es) *	2008-03-13	2011-03-21	Biotest Ag	Agente para tratar enfermedad.
ES2610327T3 (es) *	2008-03-13	2017-04-27	Biotest Ag	Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
TW201438738A (zh)	2008-09-16	2014-10-16	Genentech Inc	治療進展型多發性硬化症之方法
CN102215867B (zh) *	2008-09-29	2017-04-19	生物测试股份公司	疾病治疗用组合物
CN106153918A (zh) *	2008-10-14	2016-11-23	卡里斯Mpi公司	描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶
EP2359139B1 (en) *	2008-11-07	2018-03-07	National Jewish Health	Diagnosis and treatment of autommune diseases by targeting autommune-related b cells ("abcs")
EP3181705A1 (en) *	2008-11-12	2017-06-21	Caris Life Sciences Switzerland Holdings GmbH	Methods and systems of using exosomes for determining phenotypes
AR074357A1 (es) *	2008-11-17	2011-01-12	Genentech Inc	Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
CA2742990A1 (en) *	2008-11-17	2010-05-20	Genentech, Inc.	Method and formulation for reducing aggregation of a macromolecule under physiological conditions
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
CA2744670C (en) *	2009-01-06	2018-05-15	Ziad Mallat	A b cell depleting agent for the treatment of atherosclerosis
JP5246709B2 (ja) *	2009-06-09	2013-07-24	独立行政法人医薬基盤研究所	自己免疫疾患検査用バイオマーカー及び検査方法
US20120237472A1 (en) *	2009-07-24	2012-09-20	The Johns Hopkins University	Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2501800A4 (en)	2009-11-17	2013-05-22	Musc Found For Res Dev	HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN NUCLEOLIN
GB0920944D0 (en)	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN102933231B (zh)	2010-02-10	2015-07-29	伊缪诺金公司	Cd20抗体及其用途
KR20130056855A (ko)	2010-03-01	2013-05-30	카리스 라이프 사이언스 룩셈부르크 홀딩스	치료진단용 생물학적 지표들
WO2011127219A1 (en)	2010-04-06	2011-10-13	Caris Life Sciences Luxembourg Holdings	Circulating biomarkers for disease
JP5899206B2 (ja) *	2010-04-28	2016-04-06	オンコイミューン，インコーポレイテッド	関節リウマチの治療のための可溶性ｃｄ２４の使用方法
EP2580593A4 (en) *	2010-06-10	2014-04-16	Myra Lipes	DIAGNOSIS OF MYOCARDIAL AUTOIMMUNITY IN HEART DISEASES
CA2807552A1 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
SMT202200321T1 (it)	2010-10-01	2022-09-14	Modernatx Inc	Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
WO2012135805A2 (en)	2011-03-31	2012-10-04	modeRNA Therapeutics	Delivery and formulation of engineered nucleic acids
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
ES2911677T3 (es)	2011-10-03	2022-05-20	Modernatx Inc	Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
TWI589299B (zh) *	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en)	2011-10-11	2018-04-17	Sanofi Biotechnology	Methods for the treatment of rheumatoid arthritis
US20130156849A1 (en)	2011-12-16	2013-06-20	modeRNA Therapeutics	Modified nucleoside, nucleotide, and nucleic acid compositions
US9823246B2 (en)	2011-12-28	2017-11-21	The Board Of Trustees Of The Leland Stanford Junior University	Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon
EP2834260A4 (en)	2012-04-02	2016-08-10	Moderna Therapeutics Inc	MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US20140075585A1 (en) *	2012-09-12	2014-03-13	Futwan Al-Mohanna	Tetraspanin CD82 as a Diagnostic and/or Therapeutic Module for Xenograft Recognition and/or Rejection
HU230680B1 (hu) *	2012-10-19	2017-08-28	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Diagnosztikai eljárás
HRP20220607T1 (hr)	2012-11-26	2022-06-24	Modernatx, Inc.	Terminalno modificirana rna
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2015028662A1 (en) *	2013-08-30	2015-03-05	Consejo Superior De Investigaciones Cientificas (Csic)	Compositions and methods for characterization and amelioration of rheumatoid arthritis
EP3052106A4 (en)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru)	2013-10-03	2016-08-31	Модерна Терапьютикс, Инк.	Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
US20160146799A1 (en)	2014-11-05	2016-05-26	Nirmidas Biotech, Inc.	Metal composites for enhanced imaging
AR104368A1 (es)	2015-04-03	2017-07-19	Lilly Co Eli	Anticuerpos biespecíficos anti-cd20- / anti-baff
CN108472379B (zh)	2015-12-30	2022-06-21	豪夫迈·罗氏有限公司	减少聚山梨酯降解的制剂
IT201700110784A1 (it) *	2017-10-03	2019-04-03	Fidia Farm Spa	Composizioni farmaceutiche contenenti Acido Ialuronico e Carnosina e relativo uso
EP3520803A1 (en) *	2018-01-31	2019-08-07	Zarodex Therapeutics Limited	Novel uses
CR20200441A (es)	2018-02-27	2021-03-15	Incyte Corp	Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
US11692042B2 (en)	2018-03-09	2023-07-04	Agenus Inc.	Anti-CD73 antibodies and methods of use thereof
CN110090228A (zh) *	2018-04-18	2019-08-06	浙江大学	人羊膜上皮细胞在自身免疫性疾病中的治疗用途
US11180547B2 (en)	2018-05-08	2021-11-23	Ten Peaks LLC	Methods for reducing drug-induced liver injury
US11124566B2 (en)	2018-05-08	2021-09-21	Ten Peaks LLC	Methods for reducing drug-induced liver injury
US10519227B2 (en)	2018-05-08	2019-12-31	Ten Peaks LLC	Methods for reducing drug-induced liver injury
MX2020012376A (es)	2018-05-18	2021-03-09	Incyte Corp	Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
IL279829B2 (en)	2018-07-05	2025-05-01	Incyte Holdings Corp	Fused pyrazine derivatives as A2A/A2B inhibitors
KR20210049871A (ko)	2018-08-29	2021-05-06	리제너론 파아마슈티컬스, 인크.	류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
WO2020054979A1 (ko) *	2018-09-12	2020-03-19	아주대학교산학협력단	Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
RU2724469C2 (ru)	2018-10-31	2020-06-23	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с cd20
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20210122810A (ko)	2019-01-31	2021-10-12	사노피 바이오테크놀로지	청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
CN118546960A (zh)	2019-03-05	2024-08-27	恩卡尔塔公司	Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CN114651010A (zh)	2019-04-24	2022-06-21	赛诺菲生物技术公司	类风湿性关节炎的诊断和治疗方法
EP3980459A1 (en)	2019-06-04	2022-04-13	Sanofi Biotechnology	Compositions and methods for treating pain in subj ects with rheumatoid arthritis
US11634500B2 (en)	2019-09-06	2023-04-25	Les Laboratoires Servier	Anti-CD73 antibodies and compositions
PH12022551621A1 (en)	2020-01-03	2023-10-23	Incyte Corp	Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
US12018089B2 (en)	2020-01-03	2024-06-25	Incyte Corporation	Anti-CD73 antibodies and uses thereof
EP4014993A1 (en) *	2020-12-21	2022-06-22	Stichting Sint Maartenskliniek	Rituximab for treatment of polymyalgia rheumatica
MX2023007850A (es)	2020-12-29	2023-09-11	Incyte Corp	Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
IL47062A (en)	1975-04-10	1979-07-25	Yeda Res & Dev	Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en)	1979-03-19	1987-05-12	The Upjohn Company	Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
WO1981001145A1 (en)	1979-10-18	1981-04-30	Univ Illinois	Hydrolytic enzyme-activatible pro-drugs
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en)	1987-03-09	1987-04-15	Carlton Med Prod	Drug delivery systems
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0308936B1 (en)	1987-09-23	1994-07-06	Bristol-Myers Squibb Company	Antibody heteroconjugates for the killing of HIV-infected cells
US5283187A (en)	1987-11-17	1994-02-01	Brown University Research Foundation	Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5506126A (en) *	1988-02-25	1996-04-09	The General Hospital Corporation	Rapid immunoselection cloning method
HUT53672A (en)	1988-02-25	1990-11-28	Gen Hospital Corp	Quick immunoselective cloning process
IL85746A (en)	1988-03-15	1994-05-30	Yeda Res & Dev	Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) *	1988-03-17	1989-08-29	American Cyanamid Company	Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
FI891226A7 (fi)	1988-04-28	1989-10-29	The Board Of Trustees Of The Leland	Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en)	1989-01-19	1990-07-26	Dana Farber Cancer Institute	Soluble two domain cd2 protein
KR920700674A (ko)	1989-03-21	1992-08-10	원본미기재	특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en)	1989-06-29	1996-10-30	Medarex, Inc.	Bispecific reagents for aids therapy
JP3072330B2 (ja)	1989-07-19	2000-07-31	ジ・イミューン・レスポンス・コーポレーション	自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en)	1991-05-14	1992-11-26	Repligen Corporation	Heteroconjugate antibodies for treatment of hiv infection
WO1992022653A1 (en) *	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
ATE207080T1 (de)	1991-11-25	2001-11-15	Enzon Inc	Multivalente antigen-bindende proteine
DE69334255D1 (de)	1992-02-06	2009-02-12	Novartis Vaccines & Diagnostic	Marker für Krebs und biosynthetisches Bindeprotein dafür
DE69333082T2 (de)	1992-02-11	2004-05-06	Cell Genesys, Inc., Foster City	Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993025673A1 (en)	1992-06-04	1993-12-23	The Regents Of The University Of California	In vivo gene therapy with intron-free sequence of interest
DE4225853A1 (de) *	1992-08-05	1994-02-10	Behringwerke Ag	Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
DE69308573T2 (de)	1992-08-17	1997-08-07	Genentech Inc	Bispezifische immunoadhesine
PL174721B1 (pl)	1992-11-13	1998-09-30	Idec Pharma Corp	Przeciwciało monoklonalne anty-CD20
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5417972A (en)	1993-08-02	1995-05-23	The Board Of Trustees Of The Leland Stanford Junior University	Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
GB9413127D0 (en)	1994-06-30	1994-08-24	Philips Electronics Uk Ltd	Data processing apparatus
US5910486A (en)	1994-09-06	1999-06-08	Uab Research Foundation	Methods for modulating protein function in cells using, intracellular antibody homologues
WO1996012742A1 (en) *	1994-10-25	1996-05-02	Glaxo Group Limited	Binding agents for treatment of inflammatory, autoimmune or allergic diseases
US6214388B1 (en)	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US5677189A (en) *	1995-06-29	1997-10-14	Oncomembrane, Inc.	Method for quantifying sphingosine and for diagnosing platelet activation
EP1516628B1 (en)	1995-07-27	2013-08-21	Genentech, Inc.	Stable isotonic lyophilized protein formulation
JP4515542B2 (ja)	1997-02-10	2010-08-04	ジェネンテック，インコーポレイテッド	ヒレグリン変異体
US6306393B1 (en)	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
EP0999853B1 (en)	1997-06-13	2003-01-02	Genentech, Inc.	Stabilized antibody formulation
CA2293829C (en)	1997-06-24	2011-06-14	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
AU8296098A (en)	1997-07-08	1999-02-08	Board Of Regents, The University Of Texas System	Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
JP2001521909A (ja)	1997-10-31	2001-11-13	ジェネンテク・インコーポレイテッド	糖タンパク質グリコフォームを含む方法及び組成物
US6528624B1 (en)	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
US6194551B1 (en) *	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ES2292236T3 (es)	1998-04-02	2008-03-01	Genentech, Inc.	Variantes de anticuerpos y sus fragmentos.
US6242195B1 (en) *	1998-04-02	2001-06-05	Genentech, Inc.	Methods for determining binding of an analyte to a receptor
EP2990054A1 (en)	1998-08-11	2016-03-02	Biogen Inc.	Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
US6224866B1 (en)	1998-10-07	2001-05-01	Biocrystal Ltd.	Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
MXPA01004649A (es)	1998-11-09	2002-05-06	Idec Pharma Corp	Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
DK2055313T3 (en)	1998-11-09	2015-07-27	Biogen Inc	Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody
CN1763097B (zh)	1999-01-15	2011-04-13	杰南技术公司	具有改变的效应功能的多肽变体
US6897044B1 (en)	1999-01-28	2005-05-24	Biogen Idec, Inc.	Production of tetravalent antibodies
EP1035172A3 (en) *	1999-03-12	2002-11-27	Fuji Photo Film Co., Ltd.	Azomethine compound and oily magenta ink
HK1043312B (en)	1999-05-07	2006-07-28	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
DK1194167T3 (da)	1999-06-09	2009-11-16	Immunomedics Inc	Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
ITMI991299A1 (it)	1999-06-11	2000-12-11	Consiglio Nazionale Ricerche	Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de)	1999-07-02	2001-05-17	Infineon Technologies Ag	Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
CN1373672A (zh)	1999-07-12	2002-10-09	杰南技术公司	应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
US6451284B1 (en)	1999-08-11	2002-09-17	Idec Pharmaceuticals Corporation	Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
MXPA02001398A (es)	1999-08-11	2002-08-12	Idec Pharma Corp	Tratamiento de pacientes que tienen linfoma no hodgkins con lesion de medula osea con anticuerpos anti-cd20.
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
JP2001058956A (ja) *	1999-08-19	2001-03-06	Welfide Corp	自己免疫疾患予防・治療剤
AU6929100A (en)	1999-08-23	2001-03-19	Biocrystal Limited	Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
US20020006404A1 (en)	1999-11-08	2002-01-17	Idec Pharmaceuticals Corporation	Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020009427A1 (en)	2000-03-24	2002-01-24	Wolin Maurice J.	Methods of therapy for non-hodgkin's lymphoma
KR20020091170A (ko)	2000-03-31	2002-12-05	아이덱 파마슈티칼즈 코포레이션	Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
LT2857516T (lt) *	2000-04-11	2017-09-11	Genentech, Inc.	Multivalentiniai antikūnai ir jų panaudojimas
JP2003531178A (ja)	2000-04-25	2003-10-21	アイデックファーマスーティカルズコーポレイション	中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
CA2411102A1 (en) *	2000-06-20	2001-12-27	Idec Pharmaceutical Corporation	Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
JP2003535907A (ja)	2000-06-22	2003-12-02	ユニバーシティオブアイオワリサーチファウンデーション	抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
MXPA03000306A (es)	2000-07-12	2004-04-05	Idec Pharma Corp	Tratamiento de malignidades de celulas b que usan una combinacion de anticuerpos supresores de celulas b y aplicaciones relacionadas con anticuerpos moduladores inmunes.
AU2002213357A1 (en)	2000-10-20	2002-05-06	Idec Pharmaceuticals Corporation	Variant igg3 rituxan r and therapeutic use thereof
AU2002240120B2 (en)	2001-01-29	2008-05-08	Biogen Idec Inc.	Modified antibodies and methods of use
WO2002096948A2 (en)	2001-01-29	2002-12-05	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
US20030003097A1 (en)	2001-04-02	2003-01-02	Idec Pharmaceutical Corporation	Recombinant antibodies coexpressed with GnTIII
US20020197256A1 (en)	2001-04-02	2002-12-26	Genentech, Inc.	Combination therapy
JP2005515161A (ja)	2001-06-14	2005-05-26	インターミューンインコーポレイテッド	γ−インターフェロンおよびＢ細胞特異的抗体の併用療法
WO2003029296A1 (en)	2001-10-02	2003-04-10	Chiron Corporation	Human anti-cd40 antibodies
EP1519959B1 (en)	2002-02-14	2014-04-02	Immunomedics, Inc.	Anti-cd20 antibodies and fusion proteins thereof and methods of use
CA2490659C (en)	2002-06-28	2014-08-19	Syed V. S. Kashmiri	Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
WO2004056312A2 (en) *	2002-12-16	2004-07-08	Genentech, Inc.	Immunoglobulin variants and uses thereof
PT1613350E (pt)	2003-04-09	2009-06-24	Genentech Inc	Terapia de doença auto-imune num paciente com uma resposta inadequada a um inibidor de tnf-alfa
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage

2004
- 2004-04-06 PT PT04759142T patent/PT1613350E/pt unknown
- 2004-04-06 MX MXPA05010778A patent/MXPA05010778A/es active IP Right Grant
- 2004-04-06 BR BRPI0409534-0A patent/BRPI0409534A/pt not_active Application Discontinuation
- 2004-04-06 ZA ZA200507805A patent/ZA200507805B/en unknown
- 2004-04-06 EP EP09002405A patent/EP2062916A3/en not_active Withdrawn
- 2004-04-06 JP JP2006509724A patent/JP2006522811A/ja not_active Withdrawn
- 2004-04-06 ES ES04759142T patent/ES2322267T3/es not_active Expired - Lifetime
- 2004-04-06 HR HR20090325T patent/HRP20090325T1/xx unknown
- 2004-04-06 HR HR20050940A patent/HRP20050940A2/hr not_active Application Discontinuation
- 2004-04-06 RU RU2005134394/14A patent/RU2358762C9/ru not_active IP Right Cessation
- 2004-04-06 AU AU2004229376A patent/AU2004229376B2/en not_active Expired
- 2004-04-06 DE DE602004020061T patent/DE602004020061D1/de not_active Expired - Lifetime
- 2004-04-06 CN CNA2008101656563A patent/CN101371924A/zh active Pending
- 2004-04-06 EP EP04759142A patent/EP1613350B1/en not_active Revoked
- 2004-04-06 ME MEP-2008-636A patent/ME00426B/me unknown
- 2004-04-06 US US10/818,765 patent/US20040202658A1/en not_active Abandoned
- 2004-04-06 CA CA002519870A patent/CA2519870A1/en not_active Withdrawn
- 2004-04-06 CN CNA2004800161012A patent/CN1802176A/zh active Pending
- 2004-04-06 KR KR1020117008598A patent/KR20110044809A/ko not_active Withdrawn
- 2004-04-06 UA UAA200510467A patent/UA91961C2/ru unknown
- 2004-04-06 AT AT04759142T patent/ATE425766T1/de active
- 2004-04-06 UA UAA201006218A patent/UA99933C2/ru unknown
- 2004-04-06 PL PL04759142T patent/PL1613350T3/pl unknown
- 2004-04-06 KR KR1020057019095A patent/KR101092171B1/ko not_active Ceased
- 2004-04-06 SI SI200431115T patent/SI1613350T1/sl unknown
- 2004-04-06 DK DK04759142T patent/DK1613350T3/da active
- 2004-04-06 WO PCT/US2004/010509 patent/WO2004091657A2/en not_active Ceased
- 2004-04-06 RS YU20050761A patent/RS51686B/sr unknown
- 2004-04-06 NZ NZ587776A patent/NZ587776A/en not_active IP Right Cessation
2005
- 2005-09-22 IL IL171038A patent/IL171038A/en active IP Right Grant
- 2005-09-23 TN TNP2005000234A patent/TNSN05234A1/en unknown
- 2005-10-06 CR CR8033A patent/CR8033A/es not_active Application Discontinuation
- 2005-10-07 EC EC2005006082A patent/ECSP056082A/es unknown
- 2005-11-08 NO NO20055253A patent/NO20055253L/no unknown
- 2005-11-09 MA MA28595A patent/MA27838A1/fr unknown
2006
- 2006-05-24 US US11/439,906 patent/US7708994B2/en active Active
2008
- 2008-03-20 US US12/052,606 patent/US7976838B2/en not_active Expired - Lifetime
2009
- 2009-06-04 CY CY20091100598T patent/CY1109127T1/el unknown
- 2009-10-01 NZ NZ580116A patent/NZ580116A/en not_active IP Right Cessation
- 2009-10-13 JP JP2009235927A patent/JP2010047586A/ja not_active Withdrawn
- 2009-12-29 IL IL203019A patent/IL203019A/en active IP Right Grant
2011
- 2011-05-16 US US13/108,134 patent/US20110300136A1/en not_active Abandoned
2013
- 2013-03-01 JP JP2013040359A patent/JP5746243B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2322267T3 (es)	2009-06-18
KR20110044809A (ko)	2011-04-29
US20060240008A1 (en)	2006-10-26
KR20050114273A (ko)	2005-12-05
TNSN05234A1 (en)	2007-06-11
KR101092171B1 (ko)	2011-12-13
EP1613350A2 (en)	2006-01-11
RU2358762C2 (ru)	2009-06-20
US7708994B2 (en)	2010-05-04
ME00426B (me)	2011-10-10
JP2006522811A (ja)	2006-10-05
JP2010047586A (ja)	2010-03-04
EP2062916A3 (en)	2009-08-19
AU2004229376A1 (en)	2004-10-28
SI1613350T1 (sl)	2009-08-31
DK1613350T3 (da)	2009-06-22
ATE425766T1 (de)	2009-04-15
JP5746243B2 (ja)	2015-07-08
RU2005134394A (ru)	2006-05-27
WO2004091657A3 (en)	2005-02-10
DE602004020061D1 (de)	2009-04-30
CY1109127T1 (el)	2014-07-02
AU2004229376B2 (en)	2007-12-13
UA91961C2 (ru)	2010-09-27
US20110300136A1 (en)	2011-12-08
CA2519870A1 (en)	2004-10-28
BRPI0409534A (pt)	2006-04-18
IL203019A (en)	2012-02-29
EP1613350B1 (en)	2009-03-18
RU2358762C9 (ru)	2016-10-10
JP2013151515A (ja)	2013-08-08
NZ580116A (en)	2011-06-30
MXPA05010778A (es)	2005-12-12
NZ587776A (en)	2012-03-30
RS51686B (sr)	2011-10-31
EP2062916A2 (en)	2009-05-27
PT1613350E (pt)	2009-06-24
US20080213280A1 (en)	2008-09-04
HK1086480A1 (en)	2006-09-22
WO2004091657A2 (en)	2004-10-28
CN1802176A (zh)	2006-07-12
HRP20050940A2 (en)	2005-12-31
CN101371924A (zh)	2009-02-25
US20040202658A1 (en)	2004-10-14
MA27838A1 (fr)	2006-04-03
UA99933C2 (ru)	2012-10-25
ZA200507805B (en)	2006-12-27
ECSP056082A (es)	2006-04-19
HRP20090325T1 (en)	2009-07-31
RS20050761A (sr)	2007-11-15
IL171038A (en)	2010-06-30
US7976838B2 (en)	2011-07-12
CR8033A (es)	2006-08-18
NO20055253L (no)	2005-11-08

Publication	Publication Date	Title
PT1613350E (pt)	2009-06-24	Terapia de doença auto-imune num paciente com uma resposta inadequada a um inibidor de tnf-alfa
UY28258A1 (es)	2004-11-30	Tratamiento terapeutico
BR122019002626A2 (pl)	2019-04-02
EP1730148A4 (en)	2009-08-19	USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
ATE461217T1 (de)	2010-04-15	Glp-1-verbindungen
IL186616A (en)	2017-09-28	Spyro-oxa-indoles and their use as drugs
IL146005A0 (en)	2002-07-25	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
IL186615A0 (en)	2008-01-20	Spiroheterocylic compounds and their uses as therapeutic agents
EP1786509A4 (en)	2010-01-13	THALAMIC STIMULATION DEVICE
TW200510398A (en)	2005-03-16	Novel compounds
WO2006009718A3 (en)	2007-07-12	Methods for treating or preventing erectile dysfunction or urinary incontinence
TWI365187B (en)	2012-06-01	7-azaindoles and the use thereof as therapeutic agents
EP1649870A3 (en)	2006-05-03	Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
EA200801861A1 (ru)	2010-06-30	Активаторы плазминогена, имеющие сниженную способность связывать лизин
ITTV20050186A1 (it)	2007-06-01	Lettino per l'abbronzatura del corpo.
WO2007117289A3 (en)	2008-01-03	Methods for treating or preventing erectile dysfunction or urinary incontinence
MX2007004040A (es)	2007-05-24	Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
GB0416934D0 (en)	2004-09-01	Therapeutic agents
TW200611700A (en)	2006-04-16	New use of tetramethylpyrazine in the treatment of brain tumor
GB0401016D0 (en)	2004-02-18	Animal treat
UA2826U (uk)	2004-08-16	Спосіб лікування розсіяного склерозу
GB0400231D0 (en)	2004-02-11	Therapeutic agents
GB0425209D0 (en)	2004-12-15	Therapeutic agents
GB0422284D0 (en)	2004-11-10	Therapeutic agents
ITPD20050045U1 (it)	2006-12-01	Suoletta in cuoio e carboni attivi all'aloe vera automodellante